15 citations
,
June 2019 in “Experimental Dermatology” The authors suggest that the neuroendocrine system of the skin represents a promising target for repurposing drugs, such as cannabidiol and fingolimod, as topical treatments for inflammatory skin diseases.
2 citations
,
July 2022 in “The Kaohsiung Journal of Medical Sciences” This study demonstrated that the immunomodulatory drug FTY720 may enhance the survival of allogeneic fat grafts in mice by reducing immune rejection and improving neovascularization.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.
45 citations
,
July 2002 in “The Neurologist” This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.